The newest clinical guideline released by the ACC and American Heart Association (AHA), in collaboration with seven other societies, provides updated recommendations for perioperative cardiovascular ...

Compared with placebo, PCSK9 inhibition with evolocumab reduced the risk of first cardiovascular events among patients with atherosclerosis or diabetes and without a previous myocardial infarction or ...

Four major studies presented at AHA 2025 are reshaping strategies for managing atrial fibrillation (AFib) in complex clinical scenarios. OCEAN addresses whether ongoing anticoagulation is necessary ...

A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

NCD Academy is an online platform designed to empower the global primary care community with the knowledge, tools, and skills required to effectively address and mitigate the leading risk factors of ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

Using the ACC's health equity strategy, we aim to achieve a culture of equitable cardiovascular care and heart health for all. The ACC is paving the road to health equity through advocacy, education, ...

Learn and stay certified — all in one program: The CMP blends continuous learning with assessment, making it an efficient, effective way to grow your expertise while maintaining your credentials.

We are a young, vibrant section dedicated to adding value to Section members interested in Innovation across the cardiovascular spectrum. Our section is member-driven and focused on all aspects of ...

Asundexian was associated with a higher incidence of stroke or systemic embolism, but less major bleeding, compared with apixaban among patients with atrial fibrillation (AFib) who were at high risk ...

Sorry to break your heart. You might find something similar through our search. Please try again.